Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study

Oncology Letters

Volumn 1, Issue 4, 2010, Pages 749-753

  Leonardi, Vita ^a   Palmisano, Valentina ^a   Pepe, Alessio ^a   Usset, Antonella ^a   Manuguerra, Giovanna ^a   Savio, Giuseppina ^a   de Bella, Manuela Tamburo ^a   Laudani, Agata ^a   Alù, Massimo ^a   Cusimano, Maria Pia ^a   Scianna, Caterina ^a   Giresi, Armando ^a   Agostara, Biagio ^a  

^a Division of medical oncology   (Greece)

Author keywords

Cardiotoxicity; Metastatic breast carcinoma; Paclitaxel; Pegylated liposomal doxorubicin; Weekly chemotherapy

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER RISK; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; OVARY METASTASIS; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77954926892     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000131     Document Type: Article

References (35)

1. Early breast Cancer Trialist Group (EbCTCG): Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
2. Hortobagyi GN: Anthracyclines in the treatment of cancer: an overview. Drugs 54 (Suppl 4): 1-7, 1997.
3. Von Hoff D, Layard M, Basa P, Davcis HL, von Hoff AL, Rozencweig M and Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Inter med 91: 710-717, 1979.
4. Swain S, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879, 2003.
5. Pai VB and Nahata MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22: 263-302, 2000.
6. Balmer C and Valley AW: Basic principles of cancer treatment and cancer chemotherapy. In: Pharmacotherapy: A Pathophysiology Approach. 3rd edition. Di Piro JT, Talbert rL, yee GC, et al (eds). Appleton and Lange, Stanford, pp2403-2465, 1997.
7. Waterhouse DN, Tardi PG, Mayer LD and Balli MB: A comparison of liposomal formulation of doxorubicin with drug administered in free form: changing toxicity profles. Drug Saf 24: 903-920, 2001.
8. maluf FC and Spriggs D: Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 85: 18-31, 2002.
9. Gabizon AA: Liposomal anthracyclines. Hematol oncol Clin north Am 8: 431-450, 1994.
10. Rivera E: Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist 8 (Suppl 3): 3-9, 2003.
11. Androulakis N, Kouroussis C, Mavroudis D, Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A, Samonis G and Georgoulias V: Phase I study of weekly pacli-taxel and liposomal doxorubicin in patients with advanced solid tumours. Eur J Cancer 38: 1992-1997, 2002.
12. Perez AT, Domenech GH, Frankel C and Vogel CL: Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc. experience. Cancer Invest 20 (Suppl 2): 22-29, 2002.
13. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L and Hortobagyi GN: Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21: 3249-3254, 2003.
14. Fabi A, Ferretti G, Papaldo P, Salesi N, Ciccaresi M, Lo Russo V, Carlini P, Carpino A, Mottolese M, Cianciulli AM, Giannarelli D, Sperduti I, Felici A and Cognetti F: Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracyclines-naïve and anthracyclines pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol 57: 615-623, 2006.
15. Gebbia V, mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, Varvara F, Colombo A and Ferrera P: Pegylated liposomal doxorubicin in combination with vinorelbine in meta-static breast carcinoma. Oncology 63: 23-30, 2002.
16. Ardavanis A, mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S and Geogoulias V: Pegylated liposomal doxorubicin with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase phase II study. Cancer Chemother Pharmacol 58: 742-748, 2006.
17. Overmoyer B, Silverman P, Holder LW, Tripathy D and Henderson IC: Pegylated liposomal doxorubicin and cyclo-phophamide as frst line therapy for patients with metastatic or recurrent breast cancer. Clin Cancer 6: 150-157, 2005.
18. Vandenberg TA, Trudeau M, Provencher L, Panasci LC, Yelle L, Rayson D, Latreille J, Clemons M, Giroux M and Pouliot J: Pegylated liposomal doxorubicin (PLD) with cyclophosphamide (c) as 1st-line chemotherapy for metatstatic breast cancer (mbC) patients previously treated with adjuvant anthracyclines. J Clin Oncol 24: 10627, 2006.
19. Rigatos SK, Tsavdaridis D, Athananasiadis A, Stathopoulos JG and Stathopoulos GP: Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: A phase II study. Oncol Rep 10: 1817-1819, 2003.
20. Simoncini E, Ferrari VD, Amoroso V, Valcamonico F, Grisanti S, Vassalli L, Marpicati P, Montini E, Rangoni G and Marini G: Bi-weekly administration of pegylated liposomal doxorubicin plus paclitaxel in metastatic breast cancer (mbC) patients: a phase II study. J Clin oncol 23: 844, 2005.
21. Vorobiof DA, Rapoport BL, Chasen MR, Slabber C, McMichael G, Eek R and Mohammed C: First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast 13: 219-226, 2004.
22. Rossi D, Baldelli AM, Casadei V, Fedeli SL, Alessandroni P, Catalano V, Giordani P, Ceccolini M, Graziano F and Catalano G: neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anti-Cancer Drugs 19: 733-737, 2008.
23. Alexopoulos A, Karamouzis MV, Stavrinides H, Ardavanis A, kandilis k, Stavrakakis J, Georganta C and Rigatos G: Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as frst line treatment in metastatic breast cancer. Ann oncol 15: 891-895, 2004.
24. Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Mariani L and Gasperini G: Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer res Treat 86: 249-257, 2004.
25. Sparano JA, makhson AN, Semiglazov VF, et al: Pegylated liposomal doxorubicin plus docetaxel improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from randomized phase III study. J Clin oncol 27: 4522-4529, 2009.
26. de la Fouchardiere, Largillier R, Goubely Y, Hardy-bessard AC, Slama B, Cretin J, Orfeuvre H, Paraiso D, Bachelot T and Pujade-Lauraine E: Docetaxel and pegylated liposomal doxorubicin combination as frst-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPyTToLE. Ann oncol 20: 1959-1963, 2009.
27. Vogel CL: Salvage chemotherapy of breast cancer. Semin Oncol 21: 19-24, 1996.
28. Holmes FA, Walters RS, Theriault RL, Buzdar AU, Frye DK, Hortobagyi GN, Forman AD, Newton LK and Raber MN: Phase II trial of Taxol, an active drug in the treatment of meta-static breast cancer. J natl Cancer Inst 83: 1797-1805, 1991.
29. Seidman AD, Hudis C, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J and Norton L: Dose-dense therapy with weekly-1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
30. Perez EA, Irwin DH, Patel R, Vogel CL and Kirshner J: A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer. Proc ASCo 18: 126, 1999.
31. Loffer TM: Is there a place for 'dose-dense' weekly schedules of the taxoids? Sem Oncol 25 (Suppl 12): 32-34, 1998.
32. Verrill MW, Lee J, Cameron DA, Agrawal R, Cole Ferrigan E, and Yellowlees A: Anglo-Celtic IV: frst results of a Uk national Cancer Research Network randomized phase III pharmacoge-netic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (AbC). J Clin oncol 25: LbA1005, 2007.
33. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C and Piccart M: A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EorTC 10993). Eur J Cancer 42: 882-887, 2006.
34. 2. Ann Oncol 11: 1029-1033, 2000.
35. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L and Tendler C: Reduced cardiac toxicity and comparable effcacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for frst-line treatment of metastatic breast cancer. Ann oncol 15: 440-449, 2004.